2022-09-07 | NDAQ:BBI | Press Release | Brickell Biotech Inc.
(2022-09-07 | NDAQ:BBI) Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics
Source: stockhouse.com
Stay updated with breaking news from Bernard Khor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(2022-09-07 | NDAQ:BBI) Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics
– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and...
The findings may help explain shared clinical immune features between people with Down syndrome and older individuals. such as increased autoimmunity and impaired vaccine response.